Japanese analytical technology leader HORIBA has launched a comprehensive scientific collaboration facility in Nuneaton, expanding UK access to advanced measurement technologies for biopharmaceuticals, diagnostics, and clean energy research. The 290m² facility strengthens the company’s global network of customer-focused analytical centres.
The collaboration combines GenNext’s AutoFox protein footprinting technology with Thermo Fisher’s mass spectrometry solutions to create an integrated workflow for biotherapeutic development, offering researchers enhanced capabilities for validating AI-generated protein structural models whilst streamlining complex analytical processes.
German protein technology specialist Cube Biotech has announced a significant leadership transition, appointing Michael Bencak as Chief Executive Officer whilst founder Didier Dargent assumes the Executive Chairman position. The strategic move positions the company for accelerated global expansion in drug discovery technologies.
Austrian biotech HeartBeat.bio has partnered with German AI company biotx.ai to identify and validate novel therapeutic targets for heart failure treatment. The collaboration integrates biotx.ai’s genome-wide causal mapping platform with HeartBeat.bio’s human cardiac organoid technology, aiming to accelerate precision medicine development for the 30 million patients affected globally.
BioMed X and Servier have established the first XSeed Labs facility in Europe at the Spartners incubator in Paris-Saclay. The collaboration will develop an AI-empowered platform for sterically guided design of bispecific antibodies, addressing critical constraints in cancer immunotherapy development.
Researchers at Charité – Universitätsmedizin Berlin have developed crossNN, an artificial intelligence model that can classify more than 170 cancer types using DNA methylation patterns. The system achieves 99.1% precision for brain tumours and 97.8% for pan-cancer classification, working across multiple sequencing platforms including nanopore technology.
A new pressure-driven method for generating individual droplets at microfluidic T-junctions offers precise temporal control over droplet formation. The technique, validated through theoretical modelling and experimental testing, promises to advance lab-on-a-chip technologies for chemical analysis, diagnostics, and biological research applications.
German biotechnology firm TQ Therapeutics GmbH has strategically acquired Juno Therapeutics GmbH, dramatically expanding capabilities for developing next-generation ultra-short extracorporeal cell and gene therapy systems that could transform patient access to personalised cellular treatments.
Tagomics Ltd has secured £860,000 in Innovate UK Biomedical Catalyst funding to develop a sophisticated diagnostic test for early colorectal cancer detection, forming part of a £1.2 million project that could transform cancer screening capabilities. The Cambridge-based biomarker discovery company will customise its proprietary Interlace platform to identify genetic and epigenetic mutations associated with colorectal […]
Roche has announced a strategic collaboration with Broad Clinical Labs to develop clinical applications for its Sequencing by Expansion (SBX) technology, with an initial focus on whole genome sequencing for critically ill newborns and their biological parents. The partnership aims to establish genomic sequencing as routine clinical practice in neonatal intensive care units.
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
